The startup has developed a disposable multi-needle biopsy device that enables simultaneous sampling from multiple tumor sites, enhancing diagnostic accuracy. This technology reduces the incidence of false negatives and shortens the time required for sample collection, ultimately improving patient outcomes.
Funding
$4.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current biopsy methods may lead to inaccurate diagnoses due to sampling errors, and they often require extended time for sample collection. These inefficiencies can negatively impact patient outcomes and increase healthcare costs.
Solution
OnePass Medical offers the InstaFan™, a disposable multi-needle platform designed for endoscopic ultrasound-guided fine needle aspiration/biopsy (EUS-FNA/B). InstaFan™ enables simultaneous sampling from five different locations on a tumor in a single pass, reducing sampling errors and improving diagnostic yield. The platform is also being developed for therapeutic applications, including radiofrequency ablation (RFA) and precise drug delivery directly to tumor sites. By delivering energy to multiple sites simultaneously, InstaFan enables destroying larger area in the tumor, and thus, changing the clinical outcomes and patient management.
Target Audience
The primary target audience includes gastroenterologists, oncologists, and interventional radiologists who perform biopsies and local cancer therapies, as well as hospitals and diagnostic centers.
Features
- Disposable multi-needle design for single-pass, multi-site sampling
- Enhanced diagnostic accuracy through reduced sampling errors
- Streamlined sample collection process, saving time and costs
- EUS-RFA capabilities for thermal ablation of tumors
- Precise drug delivery system for targeted cancer therapy